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Introduction: Despite recent advances in the management of septic shock, mortality remains unacceptably high.
Earlier initiation of key therapies including appropriate antimicrobials and fluid resuscitation appears to reduce the
mortality in this condition. This study examined whether early initiation of vasopressor therapy is associated with
improved survival in fluid therapy-refractory septic shock.
Methods: Utilizing a well-established database, relevant information including duration of time to vasopressor
administration following the initial documentation of recurrent/persistent hypotension associated with septic shock
was assessed in 8,670 adult patients from 28 ICUs in Canada, the United States of America, and Saudi Arabia. The
primary endpoint was survival to hospital discharge. Secondary endpoints were length of ICU and hospital stay as
well as duration of ventilator support and vasopressor dependence. Analysis involved multivariate linear and logistic
regression analysis.
Results: In total, 8,640 patients met the definition of septic shock with time of vasopressor/inotropic initiation
documented. Of these, 6,514 were suitable for analysis. The overall unadjusted hospital mortality rate was 53%.
Independent mortality correlates included liver failure (odds ratio (OR) 3.46, 95% confidence interval (CI), 2.67 to
4.48), metastatic cancer (OR 1.63, CI, 1.32 to 2.01), AIDS (OR 1.91, CI, 1.29 to 2.49), hematologic malignancy (OR 1.88,
CI, 1.46 to 2.41), neutropenia (OR 1.78, CI, 1.27 to 2.49) and chronic hypertension (OR 0.62 CI, 0.52 to 0.73). Delay of
initiation of appropriate antimicrobial therapy (OR 1.07/hr, CI, 1.06 to 1.08), age (OR 1.03/yr, CI, 1.02 to 1.03), and
Acute Physiology and Chronic Health Evaluation (APACHE) II Score (OR 1.11/point, CI, 1.10 to 1.12) were also found
to be significant independent correlates of mortality. After adjustment, only a weak correlation between vasopressor
delay and hospital mortality was found (adjusted OR 1.02/hr, 95% CI 1.01 to 1.03, P <0.001). This weak effect was
entirely driven by the group of patients with the longest delays (>14.1 hours). There was no significant relationship of
vasopressor initiation delay to duration of vasopressor therapy (P = 0.313) and only a trend to longer duration of
ventilator support (P = 0.055) among survivors.
Conclusion: Marked delays in initiation of vasopressor/inotropic therapy are associated with a small increase in
mortality risk in patients with septic shock.Introduction
Despite advancements in understanding and treatment,
septic shock remains a worldwide healthcare problem.
With an increasing annual incidence in the developed
world, mortality remains between 25 and 50% of those
afflicted [1-3]. The pathophysiology of septic shock is* Correspondence: akumar61@yahoo.com
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hypovolemia, myocardial dysfunction, increased metabolic
rate and altered regional and microvascular blood flow
[4-11]. Septic shock appears to cause a loss of autoreg-
ulation, making the perfusion of many vital organs and
tissues dependent on blood pressure [5,12,13]. Early
and aggressive fluid resuscitation of sepsis has been
suggested to have a critical role in optimization of
organ perfusion, preservation of end organ function
and improvement of survival [14].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apy is a defining criterion in the diagnosis of septic shock
[15]. To maintain organ perfusion, current guidelines
recommend maintaining a mean arterial pressure (MAP)
of 65 mmHg with fluid therapy and vasopressors even
when hypovolemia has not yet been resolved [15]. Accord-
ing to the Surviving Sepsis Campaign this recommenda-
tion is considered ‘strong’ although supporting evidence is
considered ‘weak’ [15].
Many studies have compared different vasopressor agents
for the resuscitation of septic shock but very few have in-
vestigated the role that the timing of vasopressor initiation
in relation to hypotension onset plays in outcome [16,17].
Methods
Study design
Data from a retrospective review of adult patients
(≥18 years old) diagnosed with septic shock was used to
create the Cooperative Antimicrobial Therapy of Septic
Shock Database (member listing in Additional file 1).
Consecutive adult septic shock patients from 28 medical
institutions in Canada, the United States and Saudi Arabia
for periods between 1996 and 2008 were retrospectively
identified using either internal ICU registries/databases
and/or International Classification of Diseases (ICD-9 or
ICD-10) coding strategies. Patients from surgical, medical
and mixed ICUs were included. Each potential case was
screened to determine eligibility to meet the criteria for
septic shock as described by the 1991 Society of Critical
Care Medicine/American College of Chest Physicians
consensus statement on sepsis definition [18]. All included
cases were required to have no other obvious cause of
shock. Each institution contributed a minimum of 50
cases. A waived consent protocol was approved by the
Health Ethics Board of the University of Manitoba and at
each individual participating center (listing in Additional
file 2). The Ethics Boards waived the need for informed
consent because of the retrospective, risk-free nature of
the study in combination with the use of de-identified
data.
Data management
Data including the time to vasopressor administration
after documentation of persistent or recurrent hypoten-
sion refractory to fluid administration were retrospectively
collected from clinical records using a uniform data
extraction template by several trained research nurses or
research assistants with medical training (medical students,
residents, fellows). All data extractors reviewed >100 charts.
Hypotension was defined as a mean blood pres-
sure <65 mmHg, a systolic blood pressure <90 mmHg,
or a decrease in systolic pressure of 40 mmHg from
the patient’s baseline consistent with the Society of
Critical Care Medicine/American College of ChestPhysicians criteria for septic shock [18]. An episode of
hypotension was considered to represent the initial onset
of septic shock when hypotension persisted from the onset
despite fluid (>2 l saline or equivalent) administration
(persistent hypotension), or when hypotension was only
transiently improved (hypotension resolution for <1 hour)
with fluid resuscitation (recurrent hypotension). Hypo-
tension that resolved following fluid resuscitation alone
(crystalloid or colloid) without subsequent clinical deteri-
oration was not considered to represent the initial onset
of septic shock-related hypotension. Similarly, patients
exclusively treated with an inotropic agent without a
vasopressor during the first 24 hours were excluded from
the database. Organ failure was determined according to
previously described criteria [3,19].
Statistical analysis
Statistical analysis was performed using SAS version 9.1
(Cary, NC USA). Descriptive statistics were used to
characterize the patient population, including mean and
standard deviation for continuous variables (or median and
inter-quartile range for skewed distributions) and frequency
and proportion for categorical variables. Empirical logit
plots were used to explore the functional form of the
association between vasopressor delay fraction (analyzed
continuously and also as categorized at decile cutpoints)
and survival to hospital discharge. The shortest time delay
decile (≤6 minutes) was excluded from the analysis as this
usually represents cases where hypotension existed for an
unknown period before arrival in the emergency depart-
ment. In this circumstance, the true time from hypotension
onset to vasopressor initiation is indeterminate.
The unadjusted association between survival to hospital
discharge and vasopressor delay was estimated using
simple logistic regression. A similar analysis was done
with respect to the occurrence of individual and total
number of organ failures after the day of shock (incremen-
tal organ failures from day 2 to day 10). A wide variety of
epidemiologic factors (age, sex), comorbidities (AIDS,
hematologic malignancy (lymphoma/leukemia/multiple
myeloma), metastatic cancer, heart disease, organ trans-
plant, hypertension, respiratory disease, renal disease,
diabetes, autoimmune conditions, thromboembolism, neu-
rological diseases), severity of illness (Acute Physiology
and Chronic Health Evaluation (APACHE) score) [20],
laboratory values (admission lactic acid and bicarbonate
levels, white cell count) and therapeutic elements (time
to initial appropriate antimicrobial therapy) were first
assessed with respect to hospital survival and organ failure
using univariate analysis. Those that were significant at
P < 0.05 were retained for inclusion in the model. Mul-
tivariable logistic regression was then used to estimate
the adjusted association and to identify independent
correlates of mortality and organ failure. Mortality and
Table 1 Epidemiologic characteristics of the study cohort
(n = 6,514)
Characteristic Number Percentage
Male gender 3,711 57.0





Metastatic cancer 566 8.7
Immunosuppressed 959 14.7
Neutropenia 321 4.9
Liver failure 508 7.8
NYHA class IV heart failure 196 3.0
Congestive heart failure 704 10.8
Acute coronary syndrome 74 1.1
Ischemic heart disease 789 12.1
Hypertension 1,245 19.1
COPD (on medications) 483 7.4





Diabetes mellitus (insulin-dependent) 568 8.7
Elective surgery 939 14.4
Emergency surgery 473 7.3
Alcohol abuse 891 13.7
Autoimmune disease 306 4.7
Organic brain disease 362 5.6
Neuromuscular disease 106 1.6
COPD, chronic obstructive pulmonary disease; NYHA, New York Heart
Association. aPresented as mean ± standard deviation.
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ratios (ORs) with 95% confidence intervals (CIs). Total
incremental organ failure after the admission day (day
2 to day 10) was analyzed using Poisson regression with
results expressed as rate ratios. Because hospital length
of stay (LOS) and ICU LOS are count variables, these
secondary outcomes were analyzed using generalized
linear regression with a negative binomial distribution
and logarithmic link function, adjusted for the same co-
variates as in the primary outcome analysis. Data are
expressed as mean ± standard deviation or median with
interquartile range as appropriate.
Results
There were a total of 8,670 patients that fit the diagnostic
criteria for septic shock. Thirty patients did not have a
time of vasopressor initiation available and were excluded.
Another 2,126 patients were excluded due to inadequate
data acquisition of other significant analytic variables,
primarily time to appropriate antimicrobial therapy
from documentation of hypotension. In total, 6,514 ob-
servations were included in this analysis.
Demographic characteristics and existing comorbidity
The baseline characteristics of the patients in the entire
cohort are presented in Table 1. The average age was
62 ± 1 years with male predominance (57.0%). The most
common existing comorbidities were diabetes inclusive
of oral hypoglycemic and insulin-requiring (26.6%),
chronic renal failure inclusive of dialysis (23.6%), and
hypertension (19.1%). Illness severity is presented in
Table 2 with the average APACHE II score being 26.1 ±
8.2. Baseline (day 1) laboratory results also presented in
Table 2 showed elevated levels of serum creatinine
(219 ± 181 μmol/l), leukocyte count (16.3 ± 16.1 × 106
cells/l), International Normalized Ratio (1.5 ± 1.4) and
serum lactate (4.8 ± 4.4 mmol/l). The heart rate was
elevated at 115 ± 29 beats/minute. Approximately 40%
of cases were due to nosocomially acquired infection
(Table 2). Culture negative and bacteremic/fungemic
patients each accounted for about one-third of the
cohort. The lungs, abdomen and urinary tract were the
most common infection sites and Escherichia coli,
Staphylococcus aureus and Streptococcus pneumoniae
were the most frequently isolated pathogens (Table 2).
Treatment characteristics
The median time to vasopressor initiation was 3 hours
(25 to 75% range: 1 to 7.1 hours). The distribution of
vasopressor use is presented in Table 3. The most com-
monly used vasopressor was norepinephrine in about
two-thirds of patients, with dopamine being the second
most common used in approximately one-half. Use of a
given vasopressor was not exclusive of use of others.Dobutamine, an inotropic agent, was used for at least
30 minutes during the first 24 hours after pressor initi-
ation in 12.2% of cases. However, inotropes were never
initiated before pressors and an intrope alone was never
used (per inclusion criteria). Steroids were used in 32%
of patients.
Outcomes
The overall unadjusted mortality rate was 53%. Unadjusted
mortality among deciles ranged from 47.6% to 63.0%
(Figure 1).
Independent correlates of mortality
The significant independent correlates of mortality from
the multivariable analysis are presented in Table 4 in
order of descending influence on mortality based on
Wald χ2 values. Among these correlates, the APACHE II
Table 2 Laboratory values and severity of illness
characteristics
Parameter Mean Standard deviation
APACHE II score 26.1 8.2
Blood assay on day 1
Creatinine (μmol/l) 219 181
Bilirubin (μmol/l) 41 84
Bicarbonate (mEq/l) 19.4 6.5
Lactate (mmol/l) 4.8 4.4
Platelets (×109/l) 196 139
International Normalized Ratio 1.8 1.4
White blood cell count (×106/l) 16.3 16.1










Skin/soft tissue 469 7.2
Central nervous system 54 8.3
Intravascular catheter 224 3.4
Primary bloodstream 379 5.8
Disseminated systemic 135 2.1
Bone and joint 42 0.6
Mediastinal 63 1
Infecting organism
Staphylococus aureus 778 17.0
Sreptococcus pneumoniae 350 7.6
Other streptococci 272 5.9
Other Gram-positive cocci 218 4.8
Escherichia coli 940 20.5




Miscellaneous bacteria 314 6.8
Candida/fungi 474 10.3
APACHE, Acute Physiology and Chronic Health Evaluation.
Table 3 Treatment and vasopressor use characteristics
Treatment Number Percentage
Steroids 1,893 21.8
Activated protein C 292 3.4
Source control required 2,564 39.4

































Figure 1 Unadjusted mortality in each pressor delay decile.
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(95% CI = 1.10 to 1.12). Antimicrobial delay was the next
most important variable, each hour of delay was associ-
ated with a 7% increase in mortality (OR = 1.07, 95%
CI = 1.06 to 1.08) and age was associated with a 2.6%
increase in mortality per year of life (OR = 1.03, 95%CI = 1.02 to 1.03). Among categorical variables, liver
failure had the strongest association with mortality
(OR = 3.46, 95% CI = 2.67 to 4.48). A history of hyperten-
sion was found to convey a protective effect (OR = 0.62,
95% CI = 0.52 to 0.73).
After adjusting for independent correlates of mortality
(AIDS, hypertension, liver failure, neutropenia, malignancy,
metastatic disease, APACHE II score and delay in appropri-
ate antimicrobials), there was a weak association of delay of
vasopressors with in-hospital mortality (adjusted OR = 1.02,
95% CI = 1.01 to 1.03, P < 0.001). To examine the impact of
delays in vasopressor initiation further, deciles of delay were
examined in the model. The results are shown in Figure 2.
At increasing delays of approximately 0.50 to 1.15 hours,
1.16 to 2.00 hours, 2.01 to 2.90 hours, 2.91 to 4.00 hours,
4.01 to 5.75 hours, 5.76 to 8.45 hours, 8.46 to 14.10 hours
and >14.10 hours (reference second decile, 7 to 30 minutes
as per the analysis protocol), the adjusted OR of survival
was significantly increased only for the final, latest decile
(OR = 1.34, 95% CI = 1.03 to 1.76, P = 0.048).
Table 4 Multivariate correlates of death in septic shock
OR 95% CI P value Wald χ2
APACHE II score (per point) 1.11 1.10 to 1.12 <0.0001 544.6
Antimicrobial delay (per hour) 1.07 1.06 to 1.08 <0.0001 335.6
Age (per year) 1.03 1.02 to 1.03 <0.0001 127.1
Liver failure 3.46 2.67 to 4.48 <0.0001 88.3
Hypertension 0.62 0.52 to 0.73 <0.0001 32.2
Hematologic malignancy 1.88 1.46 to 2.41 <0.0001 24.1
Metastatic cancer 1.63 1.32 to 2.01 <0.0001 20.4
Vasopressor delay (per hour) 1.02 1.01 to 1.03 0.0099 20.1
Neutropenia 1.78 1.27 to 2.49 0.0008 11.2
AIDS 1.91 1.29 to 2.81 0.0011 10.7
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence
interval; OR, odds ratio.































Figure 3 Mean (±95% confidence interval) incremental organ
failures (day 2 to day 10 after presentation) with increasing
pressor delays.
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of stay)
Secondary outcomes were adjusted for the same inde-
pendent predictors of mortality as the primary outcome.
In both unadjusted and adjusted analyses, a strong trend
or actual significance was found between the delay to
pressor initiation and the occurrence of organ failures.
Adjusted P values were as follows: renal, P = 0.0182;
respiratory, P < 0.0001; hematologic, P = 0.0788; central
nervous system, P = 0.0208; coagulation, P = 0.0089; meta-
bolic, P < 0.0001. Notably, in each case, the last decile
(>14.1 hours) accounted for the impact of pressor delay
on the occurrence of organ failure. In addition, the total
incremental organ failures after the day of presentation
(that is, day 2 to day 10) was associated with pressor delay.
Again, this relationship was driven by the last decile of
delay (Figure 3).
For the survivors, while controlling for significant vari-





























Figure 2 Odds ratio (±95% confidence interval) of mortality for
each pressor delay decile (reference decile, 0.11 to 0.5 hours).of hospital LOS (P = 0.19) or ICU LOS (P = 0.17). In
addition, there was no significant impact on duration of
vasopressor/inotropic therapy (P = 0.313) and only a trend
towards a longer duration of ventilator support (P = 0.055)
among survivors.
Discussion
Hypotension is a central feature in the pathophysiology
of septic shock. The duration of hypotension before
intervention in cardiogenic shock caused by massive myo-
cardial infarction, obstructive shock due to pulmonary
embolus and hypovolemic shock due to major trauma/
hemorrhage is a key determinant of survival [21-25]. Out-
come in these conditions is closely associated with earlier
initiation of therapy [21-26]. Similarly, in septic shock,
early initiation of fluid resuscitation and rapid administra-
tion of appropriate antimicrobials are critical determinants
of outcome and central tenets of management [14,27,28].
Based on these factors, we hypothesized that longer dur-
ation of hypotension without hemodynamic support using
vasopressor infusion may result in a higher mortality rate
and an increased incidence of organ failure in septic shock
patients.
Our study demonstrates that the interval between diag-
nosis of septic shock and the administration of vasopres-
sor agents is a significant although modest independent
correlate to in-hospital mortality and development of late
organ failure. The entire increasing mortality effect with
increased delays in vasopressor initiation is related to the
increased mortality in the final decile group (>14 hours
post hypotension documentation) relative to the reference
group. Similarly, increasing probability of incremental
aggregate organ failures after the day of shock (that is,
day 2 to day 10) is only seen in the highest delay decile
groups (>14 hours post hypotension documentation).
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coagulation and metabolic failures were also individually
associated with pressor delays >14 hours. Perhaps because
of the modest strength of the correlation between pressor
delay and mortality/organ failure, there is no association
in the survivor group with ICU or hospital length of
stay, ventilator duration or total vasopressor adminis-
tration time.
Studies have shown that septic shock as defined in
part by persistent hypotension is an indicator of a
marked increase in morality risk in septic states [29,30].
At least two retrospective human septic shock studies
show an increasing mortality with increasing severity and
duration of hypotension [31,32]. Varpula and colleagues
showed in 111 septic shock patients that the time spent
below a MAP of 65 mmHg in the first 48 hours was a
strong predictor of mortality [31]. In another retrospective
study, Dünser and colleagues similarly measured the
area under the curve for MAP and effect on mortality
in 274 sepsis patients [32]. This study demonstrated
that the time spent with MAP <55 mmHg was associ-
ated with increased risk of death. However, a similar
correlation did not exist with the duration when MAP
was <60 mmHg, <65 mmHg, <70 mmHg and <75 mmHg.
While there has been much study into the comparison
of vasopressors/inotropes individually and in combination
[33-35], there has been a relative paucity in the literature
regarding the timing of their initiation in septic shock.
The 2012 Surviving Sepsis Guidelines recommend that
vasopressor support be started for fluid-refractory shock
as part of the 6-hour bundle based solely on expert opin-
ion [15]. A rat model of endotoxic shock has suggested
potential benefit with a higher proportionate splanchnic
blood flow, lower lactate levels and less overall fluid
support requirement for early compared with delayed nor-
epinephrine administration [36]. A porcine model of fecal
peritonitis/shock has demonstrated that delayed resuscita-
tion (inclusive of antibiotics, fluids and pressors) was asso-
ciated with increased physiologic instability and higher
pressor requirements [37]. Conversely, in a small (n = 95)
retrospective human study, no difference in organ dys-
function or ICU LOS was noted with early (<1.37 hours)
versus late (>1.37 hours) administration of vasopressors
[16]. These studies have their limitations in that two were
animal studies and none utilized survival as an endpoint.
In our study, the timing of initiation of vasopressors
following documentation of hypotension is only weakly
associated with mortality in septic shock, as indicated
by the low Wald X2 values in Table 4. The Wald X2 value
for delays in antimicrobial initiation, the other remediable
treatment parameter in the multivariate analysis, is 16.7
times higher. Note that this does not suggest that dur-
ation of hypotension before resuscitation (inclusive of
appropriate antimicrobials and fluid resuscitation) is onlyweakly correlated to outcome. On the contrary, appropri-
ate antimicrobial delays relative to hypotension and early
fluid resuscitation are well established to have critical roles
in improving outcome of septic shock [14,28]. Only the
delay of vasopressors appears to have a limited impact on
outcome in this retrospective analysis.
Given the modest strength of the association, the statis-
tical significance of time to vasopressor initiation relates
primarily to the extraordinarily large number of cases in
this dataset. The only decile group that appears to carry an
increased mortality or specific organ failure risk relative to
the reference group is the latest group (>14 hours post
hypotension documentation). All included deciles to that
point appear to carry no significant increased mortality or
specific organ failure risk after adjustment for multiple
morbid/epidemiologic factors. This finding is entirely con-
gruent with the findings of Subramanian and colleagues,
who showed no impact of vasopressor delays up to 12 hours
on organ function in a smaller cohort of <100 patients [16].
A history of hypertension conveying a protective effect
was an unexpected result on multivariate analysis. It is
possible that this finding may be explained by user bias,
in that these patients may have activated the healthcare
system more frequently to gain a diagnosis of an otherwise
silent condition. Hypertension is normally a silent condi-
tion, which may suggest that these patients had more rou-
tine access to medical care. Alternatively, the study entry
criteria (decrease in systolic pressure >40 mmHg) used for
many of these patients may be overly sensitive with respect
to diagnosing septic shock. The impact of antimicrobial
delay on mortality is not surprising because an earlier ver-
sion of this database demonstrated this same finding [28]
and animal studies demonstrate parallel results [38,39].
Overall, the results of this study are congruent with
the limited available human data. The study contributes
significantly by adding statistical power with a larger
sample size while correcting for known confounders
(antimicrobial delay, disease severity). There are still
significant study limitations. The study did control for
delays in antimicrobial administration. However, we were
unable to adjust for early fluid administration using this
dataset. Although fluid resuscitation is considered a
vital part of the initial resuscitation by emergency room
physicians and intensivists [15], there are studies suggesting
increased mortality associated with over-resuscitation of
fluids [40,41]. Other studies conversely suggest increased
mortality with under-resuscitation with fluids [14,42].
Significant interactions between the timing of vasopressor
initiation and early fluid resuscitation that we are unable
to capture in this dataset may exist. This is a significant
limitation of this study and future analyses should also
attempt to factor in fluid resuscitation.
There are other limitations to this study. This is a retro-
spective review with its inherent inability to account for
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a randomized controlled trial of timing of vasopressor
initiation in any critical illness. Given the ethical concerns
of exposing moribund patients to potential harm, a
prospective, randomized human study of timing of
vasopressor initiation in septic shock would be challen-
ging. Another limitation is that the use of hypotension
as the defining criteria for septic shock in this patient
group may be imperfect. MAP is at best a surrogate of
inadequate microvascular perfusion in shock. It does
not directly capture microcirculatory perfusion and
cellular injury that lead to organ dysfunction and death
[7,11,13]. Nonetheless, other metabolic markers such as
serum lactate and bicarbonate levels as well as severity of
illness scores (APACHE II scores) were incorporated into
the model to help adjust for variations in shock severity.
Despite these limitations of blood pressure monitoring,
given its universal access and ease of use it is the most
relied upon clinical parameter for guiding therapy and
will remain a mainstay in the treatment of septic shock
for the foreseeable future.
Conclusion
From this study, we conclude that markedly delayed initi-
ation of vasopressor medications in patients with septic
shock is modestly associated with increased organ failure
risk and decreased survival. Substantial delays of vasopres-
sor initiation (>14 hours after hypotension documentation)
are required to see these effects. Given the almost universal
use of vasopressors in septic shock and the critical need for
precise titration, further study of this area is warranted.
Key messages
 Delays in initiation of vasopressor therapy following
the first documentation of hypotension in septic
shock are modestly associated with increased
specific organ failure and mortality risk.
 This increase in specific organ failure and mortality
risk is entirely driven by the decile of patients with
the greatest delays of >14 hours.
 Vasopressor initiation delays are not associated with
increased time on vasopressors or on mechanical
ventilation among survivors.
 Delay of initiation of appropriate antimicrobial, age
and APACHE II score are also independent
correlates of mortality.
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